Smith D J, Feil V J, Huwe J K, Paulson G D
Agricultural Research Service, Biosciences Research Laboratory, Fargo, ND 58105-5674.
Drug Metab Dispos. 1993 Jul-Aug;21(4):624-33.
Ractopamine HCl, ((1R*,3R*),(1R*,3S*)-4-hydroxy-alpha-[[[3-(4- hydroxyphenyl)-1-methylpropyl]-amino]methyl]benzenemethanol hydrochloride), is a beta-adrenergic agonist that is under evaluation as a nutrient repartitioning agent in livestock. Because ractopamine metabolism has not been evaluated in turkeys, the objectives of this study were to synthesize and identify products of ractopamine metabolism and to determine the stereoselective metabolism and tissue distribution of [14C]ractopamine HCl in orally dosed turkey poults. Glucuronides of diastereoisomeric [14C]ractopamine, and the (1R,3R) and (1R,3S) stereoisomers of ractopamine were synthesized by use of microsomal proteins immobilized on Sepharose beads. Monoglucuronides conjugated to the phenols at C-10 or C-10' were isolated and identified by 1H-NMR and negative ion FAB/MS. Urine and feces were collected from colostomized turkey poults after oral dosing with 20 mg of [14C]ractopamine HCl (9.28 microCi). Radioactive residues in tissues were highest in the gallbladder and liver. Radioactivity was not detectable in blood 48 hr after dosing and was slightly above background (< 100 dpm/g tissue) in skeletal and cardiac muscle. Urine contained 47.5% of the administered radioactivity by 16 hr after dosing, and by 48 hr 52.0% of the radioactivity was excreted in the urine. Feces contained 36.6% and 41.5% of the dose 16 and 48 hr after dosing, respectively. Unmetabolized ractopamine represented only 8% of the urinary radioactivity; ractopamine glucuronides represented 72% of the urinary radioactivity. Glucuronides conjugated to the C-10 phenol of ractopamine represented 59.8% of the urinary metabolites and were composed of all four ractopamine stereoisomers. Glucuronides conjugated to the C-10' phenol of ractopamine represented 12.7% of the urinary metabolites and were composed of the (1R,3R) and (1R,3S) stereoisomers. Ractopamine was rapidly eliminated from turkeys after oral dosing, and glucuronidation was the major pathway of metabolism. Regioselective glucuronidation occurred favoring the C-10 phenol of ractopamine; glucuronidation of the C-10' phenol of ractopamine was specific for the (1R,3R) and (1R,3S) stereoisomers.
盐酸莱克多巴胺,即((1R*,3R*),(1R*,3S*)-4-羟基-α-[[[3-(4-羟基苯基)-1-甲基丙基]氨基]甲基]苯甲醇盐酸盐),是一种β-肾上腺素能激动剂,正作为家畜营养重新分配剂进行评估。由于尚未对火鸡体内的莱克多巴胺代谢进行评估,本研究的目的是合成并鉴定莱克多巴胺的代谢产物,以及确定口服给予[14C]盐酸莱克多巴胺后在火鸡雏鸡体内的立体选择性代谢和组织分布。通过使用固定在琼脂糖珠上的微粒体蛋白合成了非对映异构体[14C]莱克多巴胺的葡糖醛酸苷以及莱克多巴胺的(1R,3R)和(1R,3S)立体异构体。通过1H-NMR和负离子FAB/MS分离并鉴定了与C-10或C-10'位酚结合的单葡糖醛酸苷。给结肠造口的火鸡雏鸡口服20 mg[14C]盐酸莱克多巴胺(9.28微居里)后收集尿液和粪便。组织中的放射性残留以胆囊和肝脏中最高。给药后48小时血液中未检测到放射性,骨骼肌和心肌中的放射性略高于本底(<100 dpm/g组织)。给药后16小时尿液中含有给药放射性的47.5%,到48小时52.0%的放射性从尿液中排出。给药后16小时和48小时粪便中分别含有剂量的36.6%和41.5%。未代谢的莱克多巴胺仅占尿液放射性的8%;莱克多巴胺葡糖醛酸苷占尿液放射性的72%。与莱克多巴胺C-10位酚结合的葡糖醛酸苷占尿液代谢产物的59.8%,由所有四种莱克多巴胺立体异构体组成。与莱克多巴胺C-10'位酚结合的葡糖醛酸苷占尿液代谢产物的12.7%,由(1R,3R)和(1R,3S)立体异构体组成。口服给药后莱克多巴胺在火鸡体内迅速消除,葡糖醛酸化是主要的代谢途径。区域选择性葡糖醛酸化倾向于莱克多巴胺的C-10位酚;莱克多巴胺C-10'位酚的葡糖醛酸化对(1R,3R)和(1R,3S)立体异构体具有特异性。